Sun Pharma Discloses Auditor Registration Details in Regulatory Filing
India's pharmaceutical giant files quarterly review documentation with auditor firm credentials as part of standard compliance procedures.
Auditor Credentials Disclosed
Sun Pharmaceutical Industries Limited filed documentation on July 31, 2026, disclosing registration details for the chartered accountancy firm conducting its quarterly financial review. The filing identifies S RBC & CO LLP as the independent auditor, a Limited Liability Partnership with LLP Identity Number AAB-4318 and registered office at 22 Camac Street, Block 'B', 3rd Floor, Kolkata-700016 (Other Financials filing, 2026-07-31).
The documentation was submitted as part of the company's quarterly compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, alongside the unaudited standalone and consolidated financial results for Q1 of FY 2026-27.
Review Report Structure
The filing includes separate limited review reports for both standalone and consolidated financial results. Partner Amit Singh, with membership number 408869, signed both reports on behalf of S RBC & CO LLP from Mumbai on July 31, 2026 (Other Financials filing, 2026-07-31).
For the consolidated review, the auditor noted reliance on the work of other independent auditors who reviewed 23 subsidiaries. These entities collectively accounted for ₹34,542.6 million in revenue, ₹3,505.9 million in net profit after tax, and ₹3,504.1 million in total comprehensive income for the quarter ended June 30, 2026 (Other Financials filing, 2026-07-31).
Compliance Framework
The reviews were conducted in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India. The auditor noted that such reviews are "substantially less in scope than an audit conducted in accordance with Standards on Auditing" and accordingly does not constitute an audit opinion (Other Financials filing, 2026-07-31).
Based on the review conducted, S RBC & CO LLP stated that "nothing has come to our attention that causes us to believe" that the financial statements contain material misstatements or fail to comply with disclosure requirements under the listing regulations (Other Financials filing, 2026-07-31).
Board Meeting Timeline
The filing was submitted following a board meeting that commenced at 10:50 AM on July 31, 2026. Company Secretary and Compliance Officer Anoop Deshpande (ICSI Membership No.: A23983) noted that the meeting "is ongoing and has been temporarily adjourned for a break and will resume for consideration of other agenda items" (Other Financials filing, 2026-07-31).
The documentation forms part of Sun Pharma's standard quarterly reporting process to the National Stock Exchange of India Limited and BSE Limited, where the company trades under codes SUNPHARMA and 524715, respectively.
According to MarginX data, Sun Pharmaceutical Industries Limited is expected to report first-half 2027 results on October 30, 2026. Recent insider activity shows Life Insurance Corporation of India acquired 202,500 shares.
This article was generated by MarginX from the Other Financials filing on 2026-07-31. It is not investment advice.